Lipella Pharmaceuticals Inc.
13F holders, Q2 2024 (June 30)7holders −2
2new positions
4sold out
$0.45avg. 13F price*
At the end of Q2 2024, 7 institutions reported holding Lipella Pharmaceuticals Inc. in their 13F filings, down 2 from Q1 2024. 2 opened new positions and 4 sold out. The largest holders were Sabby Management, LLC ($243K), Vanguard Group Inc. ($16K) and Geode Capital Management, LLC ($12K).
- Company
- Lipella Pharmaceuticals Inc.
- CUSIP
- 53630L100
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $4K |
| Exits | 4 | $22K |
All 13F filers, Q1 2024 → Q2 2024: 299,182 shares bought and 48,686 shares sold, net +250,496 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Sabby Management, LLC | 3.62% | Add +116.2% | 540,250 | $243K |
| Vanguard Group Inc. | 0.00% | No change | 34,520 | $16K |
| Geode Capital Management, LLC | 0.00% | Reduce -38.2% | 25,998 | $12K |
| Two Sigma Investments, LP | 0.00% | Reduce -0.7% | 12,984 | $6K |
| UBS Group AG | 0.00% | New | 8,775 | $4K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +0.1% | 7,718 | $3K |
| Bank of America Corp. | 0.00% | New | 46 | $21 |
"% of holder's portfolio" is LIPELLA PHARMACEUTICALS INC's weight in each manager's 13F, not the share of Lipella Pharmaceuticals Inc. the manager owns.